On December 17, 2025, Tenax Therapeutics, Inc. reported that its Phase 3 clinical trial for TNX-103 is over 90% powered to detect a 25 meter improvement in patients' 6-minute walk distance, confirming its target enrollment and initiating a second Phase 3 study.